Literature DB >> 23583273

Evidence that low protein C contributes to the procoagulant imbalance in cirrhosis.

Armando Tripodi1, Massimo Primignani, Laura Lemma, Veena Chantarangkul, Pier Mannuccio Mannucci.   

Abstract

BACKGROUND & AIMS: Cirrhosis is associated with a plasmatic procoagulant imbalance, detected in vitro by thrombin generation tests performed in the presence vs. absence of such activators of protein C as thrombomodulin or Protac. This imbalance is thought to be due to decreased protein C and increased factor VIII, but this has never been directly demonstrated. To test this hypothesis we analyzed plasma from 50 patients with cirrhosis before and after in vitro addition of purified protein C meant to restore normal levels.
METHODS: Results for two thrombin generation assays were expressed as ratios of endogenous thrombin potential (ETP) with-to-without thrombomodulin or as Protac-induced coagulation inhibition (PICI%). By definition, high ETP ratios or low PICI% reflect a resistance to the anticoagulant action of thrombomodulin or Protac, respectively, and can be taken as indexes of in vitro procoagulant imbalance.
RESULTS: The median (range) protein C level before addition was 40% (4-101%) and increased to 156% (110-305) after addition (p<0.001). The procoagulant imbalance, which was high before protein C addition [ETP ratio=0.83 (0.44-1.00)], was reduced after addition [ETP ratio=0.60 (0.14-0.84)], p<0.001. ETP-ratios were inversely correlated with protein C activity (rho=-0.46, p<0.001). Similar results were obtained with the Protac assay.
CONCLUSIONS: The results provide evidence that low protein C contributes to the procoagulant imbalance in plasma from patients with cirrhosis. The findings may have clinical implications for the treatment or prophylaxis of thrombosis in these patients.
Copyright © 2013 European Association for the Study of the Liver. Published by Elsevier B.V. All rights reserved.

Entities:  

Keywords:  ETP; Factor VIII; PICI; Protac®; Protac®-induced-coagulation inhibition; Thrombin generation; Thrombomodulin; endogenous thrombin potential

Mesh:

Substances:

Year:  2013        PMID: 23583273     DOI: 10.1016/j.jhep.2013.03.036

Source DB:  PubMed          Journal:  J Hepatol        ISSN: 0168-8278            Impact factor:   25.083


  36 in total

Review 1.  Portal vein thrombosis in cirrhosis: Controversies and latest developments.

Authors:  Damian J Harding; M Thamara P R Perera; Frederick Chen; Simon Olliff; Dhiraj Tripathi
Journal:  World J Gastroenterol       Date:  2015-06-14       Impact factor: 5.742

Review 2.  Portal vein thrombosis in liver cirrhosis.

Authors:  Nao Kinjo; Hirofumi Kawanaka; Tomohiko Akahoshi; Yoshihiro Matsumoto; Masahiro Kamori; Yoshihiro Nagao; Naotaka Hashimoto; Hideo Uehara; Morimasa Tomikawa; Ken Shirabe; Yoshihiko Maehara
Journal:  World J Hepatol       Date:  2014-02-27

Review 3.  Bleeding Risk with Invasive Procedures in Patients with Cirrhosis and Coagulopathy.

Authors:  Nekisa Zakeri; Emmanuel A Tsochatzis
Journal:  Curr Gastroenterol Rep       Date:  2017-09

Review 4.  Nonalcoholic Fatty Liver Disease-Evidence for a Thrombophilic State?

Authors:  Margaret Spinosa; Jonathan G Stine
Journal:  Curr Pharm Des       Date:  2020       Impact factor: 3.116

Review 5.  Anticoagulation in patients with advanced liver disease: an open issue.

Authors:  Francesco Violi; Lorenzo Loffredo; Daniele Pastori
Journal:  Intern Emerg Med       Date:  2020-10-18       Impact factor: 3.397

6.  Effects of Portal Vein Thrombosis on the Outcomes of Liver Cirrhosis: A Mexican Perspective.

Authors:  Vania Cruz-Ramón; Paulina Chinchilla-López; Oscar Ramírez-Pérez; Nahum Méndez-Sánchez
Journal:  J Transl Int Med       Date:  2017-12-29

7.  Direct Oral Anticoagulants in Cirrhosis Patients Pose Similar Risks of Bleeding When Compared to Traditional Anticoagulation.

Authors:  N M Intagliata; Z H Henry; H Maitland; N L Shah; C K Argo; P G Northup; S H Caldwell
Journal:  Dig Dis Sci       Date:  2016-01-02       Impact factor: 3.199

Review 8.  Acute-on-chronic liver failure: Pathogenesis, prognostic factors and management.

Authors:  Sara Blasco-Algora; José Masegosa-Ataz; María Luisa Gutiérrez-García; Sonia Alonso-López; Conrado M Fernández-Rodríguez
Journal:  World J Gastroenterol       Date:  2015-11-14       Impact factor: 5.742

9.  Hepatocyte tissue factor contributes to the hypercoagulable state in a mouse model of chronic liver injury.

Authors:  Pierre-Emmanuel Rautou; Kohei Tatsumi; Silvio Antoniak; A Phillip Owens; Erica Sparkenbaugh; Lori A Holle; Alisa S Wolberg; Anna K Kopec; Rafal Pawlinski; James P Luyendyk; Nigel Mackman
Journal:  J Hepatol       Date:  2015-08-29       Impact factor: 25.083

10.  Circulating microparticle tissue factor activity is increased in patients with cirrhosis.

Authors:  Pierre-Emmanuel Rautou; Anne-Clémence Vion; James P Luyendyk; Nigel Mackman
Journal:  Hepatology       Date:  2014-10-01       Impact factor: 17.425

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.